Kainos Laboratories

Kainos Laboratories Current Liabilities

Delisted

The Current Liabilities of Kainos Laboratories (4556.T) as of Oct 29, 2026 is 1.46 B JPY. In the previous year, Current Liabilities was 1.98 B JPY — a change of -26.45% (lower).

Current Liabilities

1.46 BJPY

YoY

-26.45%

Last updated:

Current Liabilities of Kainos Laboratories is 2025 1.46 B JPY. Current Liabilities of Kainos Laboratories was 2024 1.98 B JPY. It decreases by -26.45% lower compared to the previous year.

The Kainos Laboratories Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
1.92 B JPY
Jan 1, 2019
1.66 B JPY
Jan 1, 2020
1.85 B JPY
Jan 1, 2021
1.89 B JPY
Jan 1, 2022
1.78 B JPY
Jan 1, 2023
1.92 B JPY
Jan 1, 2024
1.98 B JPY
Jan 1, 2025
1.46 B JPY
The Kainos Laboratories Current Liabilities history
YEARCurrent LiabilitiesYoY
1.46 BJPY-26.45%
1.98 BJPY+3.36%
1.92 BJPY+7.58%
1.78 BJPY-5.95%
1.89 BJPY+2.48%
1.85 BJPY+11.33%
1.66 BJPY-13.76%
1.92 BJPY+12.75%
1.71 BJPY-13.57%
1.98 BJPY-22.18%
2.54 BJPY+0.59%
2.52 BJPY-1.63%
2.57 BJPY-0.15%
2.57 BJPY+4.34%
2.46 BJPY+9.94%
2.24 BJPY+2.84%
2.18 BJPY+7.63%
2.02 BJPY-4.16%
2.11 BJPY+2.16%
2.07 BJPY+3.49%
2.00 BJPY+2.03%
1.96 BJPY-2.35%
2.00 BJPY-34.45%
3.06 BJPY+25.95%
2.43 BJPY-6.66%
2.60 BJPY-0.80%
2.62 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kainos Laboratories Stock analysis

What does Kainos Laboratories do? Kainos Laboratories Inc develops and manufactures pharmaceuticals, diagnostic reagents, and related chemical products for distribution and import/export. The company sells its products to healthcare providers, hospitals, and medical institutions within Japan and internationally. Its core offerings include prescription medications, diagnostic tools, and chemical compounds used in medical research and treatment. The business model relies on direct sales to medical facilities and global trade of its pharmaceutical and diagnostic solutions. Kainos Laboratories Inc focuses on the Japanese market with its headquarters in Bunkyo-Ku, Tokyo-To, while also engaging in international import/export activities. The company's revenue streams come from the sale of pharmaceuticals, diagnostic reagents, and chemical products to healthcare professionals and institutions. Its product portfolio targets medical practitioners and research organizations requiring specialized diagnostic and therapeutic solutions. The company operates with 144 full-time employees dedicated to the development, manufacturing, and distribution of its products. Kainos Laboratories Inc generates income through the commercialization of its pharmaceuticals and diagnostic reagents, serving both domestic and global clients in the healthcare sector. Sales are driven by demand for medical treatments and diagnostic tools in clinical and research settings. Kainos Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kainos Laboratories stock

Current Liabilities of Kainos Laboratories is 1.46 B JPY in 2025.

Current Liabilities of Kainos Laboratories changed from 1.98 B JPY to 1.46 B JPY, representing a -26.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Kainos Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Kainos Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Kainos Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Kainos Laboratories